Aging and the cardiac collagen matrix: Novel mediators of fibrotic remodelling

Journal of Molecular and Cellular Cardiology

Volumn 93, Issue , 2016, Pages 175-185

  Horn, Margaux A ^a   Trafford, Andrew W ^a  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Aging; Collagen; Extracellular matrix; Fibrosis; Heart failure

Indexed keywords

CARDIOTROPHIN 1; COLLAGEN; GALECTIN 3; MATRIX METALLOPROTEINASE; MICRORNA; RELAXIN; TISSUE INHIBITOR OF METALLOPROTEINASE; BIOLOGICAL MARKER;

AGE; AGING; CARDIAC REMODELING; COLLAGEN DEGRADATION; COLLAGEN SYNTHESIS; DIASTOLIC DYSFUNCTION; DISEASE ASSOCIATION; EXTRACELLULAR MATRIX; GENETIC MANIPULATION; HEART MUSCLE FIBROSIS; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW; SIGNAL TRANSDUCTION; TISSUE REGENERATION; ANIMAL; CARDIAC MUSCLE; ETIOLOGY; FIBROSIS; HEART VENTRICLE FUNCTION; HEART VENTRICLE REMODELING; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY;

AGING; ANIMALS; BIOMARKERS; COLLAGEN; EXTRACELLULAR MATRIX; FIBROSIS; HUMANS; MATRIX METALLOPROTEINASES; MYOCARDIUM; PROTEIN PROCESSING, POST-TRANSLATIONAL; TISSUE INHIBITOR OF METALLOPROTEINASES; VENTRICULAR DYSFUNCTION; VENTRICULAR REMODELING;

EID: 84949661774     PISSN: 00222828     EISSN: 10958584     Source Type: Journal    
DOI: 10.1016/j.yjmcc.2015.11.005     Document Type: Review

References (204)

1. Redfield M.M., Jacobsen S.J., Burnett J.C., Mahoney D.W., Bailey K.R., Rodeheffer R.J. Burden of systolic and diastolic ventricular dysfunction in the community: appreciating the scope of the heart failure epidemic. J. Am. Med. Assoc. 2003, 289:194-202.
2. Jugdutt B.I. Aging and heart failure: changing demographics and implications for therapy in the elderly. Heart Fail. Rev. 2010, 15:401-405.
3. Cherubini A., Oristrell J., Pla X., Ruggiero C., Ferretti R., Diestre G., et al. The persistent exclusion of older patients from ongoing clinical trials regarding heart failure. Arch. Intern. Med. 2011, 171:550-556.
4. Herrera A.P., Snipes S.A., King D.W., Torres-Vigil I., Goldberg D.S., Weinberg A.D. Disparate inclusion of older adults in clinical trials: priorities and opportunities for policy and practice change. Am. J. Public Health 2010, 100(Suppl. 1). (S105-S12).
5. Konrat C., Boutron I., Trinquart L., Auleley G.R., Ricordeau P., Ravaud P. Underrepresentation of elderly people in randomised controlled trials. The example of trials of 4 widely prescribed drugs. PLoS One 2012, 7.
6. Kajstura J., Cheng W., Sarangarajan R., Li P., Li B., Nitahara J.A., et al. Necrotic and apoptotic myocyte cell death in the aging heart of Fischer 344 rats. Am. J. Phys. 1996, 271:H1215-H1228.
7. Kung G., Konstantinidis K., Kitsis R.N. Programmed necrosis, not apoptosis, in the heart. Circ. Res. 2011, 108:1017-1036.
8. Wohlgemuth S.E., Calvani R., Marzetti E. The interplay between autophagy and mitochondrial dysfunction in oxidative stress-induced cardiac aging and pathology. J. Mol. Cell. Cardiol. 2014, 71:62-70.
9. Dai D.F., Chiao Y.A., Marcinek D.J., Szeto H.H., Rabinovitch P.S. Mitochondrial oxidative stress in aging and healthspan. Longev. Healthspan. 2014, 3:6.
10. Toprak A., Reddy J., Chen W., Srinivasan S., Berenson G. Relation of pulse pressure and arterial stiffness to concentric left ventricular hypertrophy in young men (from the Bogalusa Heart Study). Am. J. Cardiol. 2009, 103:978-984.
11. Lorell B.H., Carabello B.A. Left ventricular hypertrophy. Pathogenesis, detection and prognosis. Circulation 2000, 102:470-479.
12. Samarel A.M. Mechanotransduction in cardiomyocyte hypertrophy. Molecular Mechanisms of Cardiac Hypertrophy and Failure 2005, 89-100. Taylor & Francis, Abingdon. R.A. Walsh (Ed.).
13. Anversa P., Hiler B., Ricci R., Guideri G., Olivetti G. Myocyte cell loss and myocyte hypertrophy in the aging rat heart. J. Am. Coll. Cardiol. 1986, 8:1441-1448.
14. Olivetti G., Melissari M., Capasso J.M., Anversa P. Cardiomyopathy of the aging human heart. Myocyte loss and reactive cellular hypertrophy. Circ. Res. 1991, 68:1560-1568.
15. Biernacka A., Frangogiannis N.G. Aging and cardiac fibrosis. Aging Dis. 2011, 2:158-173.
16. Porter K.E., Turner N.A. Cardiac fibroblasts: at the heart of myocardial remodeling. Pharmacol. Ther. 2009, 123:255-278.
17. Camelliti P., Borg T.K., Kohl P. Structural and functional characterisation of cardiac fibroblasts. Cardiovasc. Res. 2005, 65:40-51.
18. Debessa C.R.G., Maifrino L.B.M., de Souza R.R. Age related changes of the collagen network of the human heart. Mech. Aging Dev. 2001, 122:1049-1058.
19. Eghbali M., Eghbali M., Robinson T.F., Seifter S., Blumenfeld O.O. Collagen accumulation in heart ventricles as a function of growth and aging. Cardiovasc. Res. 1989, 23:723-729.
20. Horn M.A., Graham H.K., Richards M.A., Clarke J.D., Greensmith D.J., Briston S.J., et al. Age-related divergent remodeling of the cardiac extracellular matrix in heart failure: collagen accumulation in the young and loss in the aged. J. Mol. Cell. Cardiol. 2012, 53:82-90.
21. Nichols W.W., O'Rourke M.F. Aging. McDonald's Blood Flow in Arteries: Theoretical, Experimental and Clinical Principles 2005, Oxford University Press Inc., New York. 5th ed.
22. Lakatta E.G., Levy D. Arterial and cardiac aging: major shareholders in cardiovascular disease enterprises: part II: the aging heart in health: links to heart disease. Circulation 2003, 107:346-354.
23. Stratton J.R., Levy W.C., Cerqueira M.D., Schwartz R.S., Abrass I.B. Cardiovascular responses to exercise. Effects of aging and exercise training in healthy men. Circulation 1994, 89:1648-1655.
24. Kitzman D.W., Gardin J.M., Gottdiener J.S., Arnold A., Boineau R., Aurigemma G., et al. Importance of heart failure with preserved systolic function in patients > or =65 years of age. CHS Research Group. Cardiovascular Health Study. Am. J. Cardiol. 2001, 87:413-419.
25. Arbab-Zadeh A., Dijk E., Prasad A., Fu Q., Torres P., Zhang R., et al. Effect of aging and physical activity on left ventricular compliance. Circulation 2004, 110:1799-1805.
26. Horn M.A. Cardiac physiology of aging: extracellular considerations. Compr. Physiol. 2015, 5:1069-1121.
27. Reed A.L., Tanaka A., Sorescu D., Liu H., Jeong E.M., Sturdy M., et al. Diastolic dysfunction is associated with cardiac fibrosis in the senescence-accelerated mouse. Am. J. Physiol. Heart Circ. Physiol. 2011, 301. (H824-H31).
28. Capasso J.M., Palackal T., Olivetti G., Anversa P. Severe myocardial dysfunction induced by ventricular remodeling in aging rat hearts. Am. J. Physiol. Heart. Circ. Physiol. 1990, 259. (H1086-H96).
29. Graham H.K., Horn M., Trafford A.W. Extracellular matrix profiles in the progression to heart failure. Acta Physiol. 2008, 194:3-21.
30. Hein S., Schaper J. The extracellular matrix in normal and diseased myocardium. J. Nucl. Cardiol. 2001, 8:188-196.
31. Behrens D.T., Villone D., Koch M., Brunner G., Sorokin L., Robenek H., et al. The epidermal basement membrane is a composite of separate laminin- or collagen IV-containing networks connected by aggregated perlecan, but not by nidogens. J. Biol. Chem. 2012, 287:18700-18709.
32. Jane-Lise S., Corda S., Chassagne C., Rappaport L. The extracellular matrix and the cytoskeleton in heart hypertrophy and failure. Heart Fail. Rev. 2000, 5:239-250.
33. Ross R.S., Borg T.K. Integrins and the myocardium. Circ. Res. 2001, 88:1112-1119.
34. Rueckschloss U., Isenberg G. Contraction augments L-type Ca2+ currents in adherent guinea-pig cardiomyocytes. J. Physiol. 2004, 560:403-411.
35. Wang Y.G., Samarel A.M., Lipsius S.L. Laminin acts via beta 1 integrin signalling to alter cholinergic regulation of L-type Ca(2+) current in cat atrial myocytes. J. Physiol. 2000, 526(Pt 1):57-68.
36. Miyamoto S., Teramoto H., Gutkind J.S., Yamada K.M. Integrins can collaborate with growth factors for phosphorylation of receptor tyrosine kinases and MAP kinase activation: roles of integrin aggregation and occupancy of receptors. J. Cell Biol. 1996, 135:1633-1642.
37. Chen C., Li R., Ross R.S., Manso A.M. Integrins and integrin-related proteins in cardiac fibrosis. J. Mol. Cell. Cardiol. 2016, 93:162-174. (in this issue).
38. Nguyen N., Yabluchanskiy A., de Castro Bras L.E., Jin Y.F., Lindsey M.L. Aging-related changes in extracellular matrix: implications for ventricular remodeling following myocardial infarction. Aging and Heart Failure: Mechanisms and Management 2014, 377-389. Springer, New York, NY. B.I. Jugdutt (Ed.).
39. Daniel L., Joyner W.L., Singh M., Singh K. Integrins: implications for aging in heart failure therapy. Aging and Heart Failure: Mechanisms and Management 2014, 401-410. Springer, New York, NY. B.I. Jugdutt (Ed.).
40. Jugdutt B.I. Ventricular remodeling after infarction and the extracellular collagen matrix: when is enough enough?. Circulation 2003, 108:1395-1403.
41. Eghbali M., Czaja M.J., Zeydel M., Weiner F.R., Zern M.A., Seifter S., et al. Collagen chain mRNAs in isolated heart cells from young and adult rats. J. Mol. Cell. Cardiol. 1988, 20:267-276.
42. Eghbali M., Blumenfeld O.O., Seifter S., Buttrick P.M., Leinwand L.A., Robinson T.F., et al. Localization of types I, III and IV collagen mRNAs in rat heart cells by in situ hybridization. J. Mol. Cell. Cardiol. 1989, 21:103-113.
43. Kohl P., Gourdie R.G. Fibroblast-myocyte electrotonic coupling: does it occur in native cardiac tissue?. J. Mol. Cell. Cardiol. 2014, 70:37-46.
44. Leask A. Getting to the heart of the matter: new insights into cardiac fibrosis. Circ. Res. 2015, 116:1269-1276.
45. Carver W., Nagpal M.L., Nachtigal M., Borg T.K., Terracio L. Collagen expression in mechanically stimulated cardiac fibroblasts. Circ. Res. 1991, 69:116-122.
46. Robinson T.F., Geraci M.A., Sonnenblick E.H., Factor S.M. Coiled perimysial fibers of papillary muscle in rat heart: morphology, distribution, and changes in configuration. Circ. Res. 1988, 63:577-592.
47. Wang B., Tedder M., Perez C., Wang G., Jongh Curry A., To F., et al. Structural and biomechanical characterizations of porcine myocardial extracellular matrix. J. Mater. Sci. Mater. Med. 2012, 23:1835-1847.
48. Mizuno T., Yau T.M., Weisel R.D., Kiani C.G., Li R.K. Elastin stabilizes an infarct and preserves ventricular function. Circulation 2005, 112:I-81.
49. Neuman R.E., Logan M.A. The determination of collagen and elastin in tissues. J. Biol. Chem. 1950, 186:549-556.
50. Bashey R.I., Martinez-Hernandez A., Jimenez S.A. Isolation, characterization, and localization of cardiac collagen type VI. Associations with other extracellular matrix components. Circ. Res. 1992, 70:1006-1017.
51. Medugorac I., Jacob R. Characterisation of left ventricular collagen in the rat. Cardiovasc. Res. 1983, 17:15-21.
52. Caulfield J.B., Norton P., Weaver R.D. Cardiac dilatation associated with collagen alterations. Mol. Cell. Biochem. 1992, 118:171-179.
53. Robinson T.F., Factor S.M., Capasso J.M., Wittenberg B.A., Blumenfeld O.O., Seifter S. Morphology, composition, and function of struts between cardiac myocytes of rat and hamster. Cell Tissue Res. 1987, 249:247-255.
54. Weber K.T., Sun Y., Bhattacharya S.K., Ahokas R.A., Gerling I.C. Myofibroblast-mediated mechanisms of pathological remodelling of the heart. Nat. Rev. Cardiol. 2013, 10:15-26.
55. Factor S.M., Robinson T.F., Dominitz R., Cho S. Alterations of the myocardial skeletal framework in acute myocardial infarction with and without ventricular rupture. A preliminary report. Am. J. Cardiovasc. Pathol. 1986, 1:91-97.
56. Jalil J.E., Doering C.W., Janicki J.S., Pick R., Shroff S.G., Weber K.T. Fibrillar collagen and myocardial stiffness in the intact hypertrophied rat left ventricle. Circ. Res. 1989, 64:1041-1050.
57. Baicu C.F., Stroud J.D., Livesay V.A., Hapke E., Holder J., Spinale F.G., et al. Changes in extracellular collagen matrix alter myocardial systolic performance. Am. J. Physiol. Heart Circ. Physiol. 2003, 284. (H122-H32).
58. Kato S., Spinale F.G., Tanaka R., Johnson W., Cooper G., Zile M.R. Inhibition of collagen cross-linking: effects on fibrillar collagen and ventricular diastolic function. Am. J. Phys. 1995, 269:H863-H868.
59. Nguyen D.T., Ding C., Wilson E., Marcus G.M., Olgin J.E. Pirfenidone mitigates left ventricular fibrosis and dysfunction after myocardial infarction and reduces arrhythmias. Heart Rhythm. 2010, 7:1438-1445.
60. Schellings M.W., Vanhoutte D., Swinnen M., Cleutjens J.P., Debets J., van Leeuwen R.E., et al. Absence of SPARC results in increased cardiac rupture and dysfunction after acute myocardial infarction. J. Exp. Med. 2009, 206:113-123.
61. Schroen B., Heymans S., Sharma U., Blankesteijn W.M., Pokharel S., Cleutjens J.P., et al. Thrombospondin-2 is essential for myocardial matrix integrity: increased expression identifies failure-prone cardiac hypertrophy. Circ. Res. 2004, 95:515-522.
62. Baicu C.F., Zhang Y., Van Laer A.O., Renaud L., Zile M.R., Bradshaw A.D. Effects of the absence of procollagen C-endopeptidase enhancer-2 on myocardial collagen accumulation in chronic pressure overload. Am. J. Physiol. Heart Circ. Physiol. 2012, 303:H234-H240.
63. Goldsmith E.C., Bradshaw A.D., Spinale F.G. Cellular mechanisms of tissue fibrosis. 2. Contributory pathways leading to myocardial fibrosis: moving beyond collagen expression. Am. J. Physiol. Cell Physiol. 2013, 304:C393-C402.
64. Kobayashi K., Luo M., Zhang Y., Wilkes D.C., Ge G., Grieskamp T., et al. Secreted Frizzled-related protein 2 is a procollagen C proteinase enhancer with a role in fibrosis associated with myocardial infarction. Nat. Cell Biol. 2009, 11:46-55.
65. Kadler K.E., Hill A., Canty-Laird E.G. Collagen fibrillogenesis: fibronectin, integrins, and minor collagens as organizers and nucleators. Curr. Opin. Cell Biol. 2008, 20:495-501.
66. Kessler E., Takahara K., Biniaminov L., Brusel M., Greenspan D.S. Bone morphogenetic protein-1: the type I procollagen C-proteinase. Science 1996, 271:360-362.
67. Rentz T.J., Poobalarahi F., Bornstein P., Sage E.H., Bradshaw A.D. SPARC regulates processing of procollagen I and collagen fibrillogenesis in dermal fibroblasts. J. Biol. Chem. 2007, 282:22062-22071.
68. Norris R.A., Damon B., Mironov V., Kasyanov V., Ramamurthi A., Moreno-Rodriguez R., et al. Periostin regulates collagen fibrillogenesis and the biomechanical properties of connective tissues. J. Cell. Biochem. 2007, 101:695-711.
69. Kadler K.E., Holmes D.F., Trotter J.A., Chapman J.A. Collagen fibril formation. Biochem. J. 1996, 316(Pt 1):1-11.
70. Kadler K.E., Hojima Y., Prockop D.J. Assembly of collagen fibrils de novo by cleavage of the type I pC-collagen with procollagen C-proteinase. Assay of critical concentration demonstrates that collagen self-assembly is a classical example of an entropy-driven process. J. Biol. Chem. 1987, 262:15696-15701.
71. Eyre D.R., Paz M.A., Gallop P.M. Cross-linking in collagen and elastin. Annu. Rev. Biochem. 1984, 53:717-748.
72. Lopez B., Gonzalez A., Hermida N., Valencia F., de Teresa E., Diez J. Role of lysyl oxidase in myocardial fibrosis: from basic science to clinical aspects. Am. J. Physiol. Heart Circ. Physiol. 2010, 299:H1-H9.
73. Hartog J.W.L., Voors A.A., Bakker S.J.L., Smit A.J., van Veldhuisen D.J. Advanced glycation end-products (AGEs) and heart failure: pathophysiology and clinical implications. Eur. J. Heart Fail. 2007, 9:1146-1155.
74. Lopez B., Querejeta R., Gonzalez A., Beaumont J., Larman M., Diez J. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 2009, 53:236-242.
75. Herum K.M., Lunde I.G., Skrbic B., Louch W.E., Hasic A., Boye S., et al. Syndecan-4 is a key determinant of collagen cross-linking and passive myocardial stiffness in the pressure-overloaded heart. Cardiovasc. Res. 2015, 106:217-226.
76. Spinale F.G. Myocardial matrix remodeling and the matrix metalloproteinases: influence on cardiac form and function. Physiol. Rev. 2007, 87:1285-1342.
77. Ma Y., Halade G.V., Zhang J., Ramirez T.A., Levin D., Voorhees A., et al. Matrix metalloproteinase-28 deletion exacerbates cardiac dysfunction and rupture after myocardial infarction in mice by inhibiting M2 macrophage activation. Circ. Res. 2013, 112:675-688.
78. Sasaki T., Gohring W., Mann K., Maurer P., Hohenester E., Knauper V., et al. Limited cleavage of extracellular matrix protein BM-40 by matrix metalloproteinases increases its affinity for collagens. J. Biol. Chem. 1997, 272:9237-9243.
79. Maurer P., Gohring W., Sasaki T., Mann K., Timpl R., Nischt R. Recombinant and tissue-derived mouse BM-40 bind to several collagen types and have increased affinities after proteolytic activation. Cell. Mol. Life Sci. 1997, 53:478-484.
80. Karsdal M.A., Larsen L., Engsig M.T., Lou H., Ferreras M., Lochter A., et al. Matrix metalloproteinase-dependent activation of latent transforming growth factor-β controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J. Biol. Chem. 2002, 277:44061-44067.
81. Zile M.R., Baicu C.F., Stroud R.E., Van Laer A.O., Jones J.A., Patel R., et al. Mechanistic relationship between membrane type-1 matrix metalloproteinase and the myocardial response to pressure overload. Circ. Heart Fail. 2014, 7:340-350.
82. Ducharme A., Frantz S., Aikawa M., Rabkin E., Lindsey M., Rohde L.E., et al. Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J. Clin. Invest. 2000, 106:55-62.
83. Hayashidani S., Tsutsui H., Ikeuchi M., Shiomi T., Matsusaka H., Kubota T., et al. Targeted deletion of MMP-2 attenuates early LV rupture and late remodeling after experimental myocardial infarction. Am. J. Physiol. Heart Circ. Physiol. 2003, 285. (H1229-H35).
84. Spinale F.G., Mukherjee R., Zavadzkas J.A., Koval C.N., Bouges S., Stroud R.E., et al. Cardiac restricted overexpression of membrane type-1 matrix metalloproteinase causes adverse myocardial remodeling following myocardial infarction. J. Biol. Chem. 2010, 285:30316-30327.
85. Vanhoutte D., Heymans S. TIMPs and cardiac remodeling: 'embracing the MMP-independent-side of the family'. J. Mol. Cell. Cardiol. 2010, 48:445-453.
86. Ikonomidis J.S., Hendrick J.W., Parkhurst A.M., Herron A.R., Escobar P.G., Dowdy K.B., et al. Accelerated LV remodeling after myocardial infarction in TIMP-1-deficient mice: effects of exogenous MMP inhibition. Am. J. Physiol. Heart Circ. Physiol. 2005, 288. (H149-H58).
87. Kandalam V., Basu R., Abraham T., Wang X., Soloway P.D., Jaworski D.M., et al. TIMP2 deficiency accelerates adverse post-myocardial infarction remodeling because of enhanced MT1-MMP activity despite lack of MMP2 activation. Circ. Res. 2010, 106:796-808.
88. Fan D., Takawale A., Basu R., Patel V., Lee J., Kandalam V., et al. Differential role of TIMP2 and TIMP3 in cardiac hypertrophy, fibrosis, and diastolic dysfunction. Cardiovasc. Res. 2014, 103:268-280.
89. Iyer R.P., de Castro Brás L.E., Jin Y.-F., Lindsey M.L. Translating Koch's postulates to identify matrix metalloproteinase roles in postmyocardial infarction remodeling: cardiac metalloproteinase actions (CarMA) postulates. Circ. Res. 2014, 114:860-871.
90. Spinale F.G. Matrix metalloproteinases: regulation and dysregulation in the failing heart. Circ. Res. 2002, 90:520-530.
91. Lin J., Lopez E.F., Jin Y., Van Remmen H., Bauch T., Han H.C., et al. Age-related cardiac muscle sarcopenia: combining experimental and mathematical modeling to identify mechanisms. Exp. Gerontol. 2008, 43:296-306.
92. Jugdutt B.I., Jelani A., Palaniyappan A., Idikio H., Uweira R.E., Menon V., et al. Aging-related early changes in markers of ventricular and matrix remodeling after reperfused ST-segment elevation myocardial infarction in the canine model: effect of early therapy with an angiotensin II type 1 receptor blocker. Circulation 2010, 122:341-351.
93. Mewton N., Liu C.Y., Croisille P., Bluemke D., Lima J.A. Assessment of myocardial fibrosis with cardiovascular magnetic resonance. J. Am. Coll. Cardiol. 2011, 57:891-903.
94. Liu C.Y., Liu Y.C., Wu C., Armstrong A., Volpe G.J., van der Geest R.J., et al. Evaluation of age-related interstitial myocardial fibrosis with cardiac magnetic resonance contrast-enhanced T1 mapping: MESA (Multi-Ethnic Study of Atherosclerosis). J. Am. Coll. Cardiol. 2013, 62:1280-1287.
95. Neilan T.G., Coelho-Filho O.R., Shah R.V., Abbasi S.A., Heydari B., Watanabe E., et al. Myocardial extracellular volume fraction from T1 measurements in healthy volunteers and mice: relationship to aging and cardiac dimensions. J. Am. Coll. Cardiol. Img. 2013, 6:672-683.
96. Boluyt M.O., O'Neill L., Meredith A.L., Bing O.H.L., Brooks W.W., Conrad C.H., et al. Alterations in cardiac gene expression during the transition from stable hypertrophy to heart failure. Circ. Res. 1994, 75:23-32.
97. Querejeta R., Lopez B., Gonzalez A., Sanchez E., Larman M., Martinez Ubago J.L., et al. Increased collagen type I synthesis in patients with heart failure of hypertensive origin: relation to myocardial fibrosis. Circulation 2004, 110:1263-1268.
98. Annoni G., Luvarà G., Arosio B., Gagliano N., Fiordaliso F., Santambrogio D., et al. Age-dependent expression of fibrosis-related genes and collagen deposition in the rat myocardium. Mech. Aging Dev. 1998, 101:57-72.
99. Thomas D.P., Zimmerman S.D., Hansen T.R., Martin D.T., McCormick R.J. Collagen gene expression in rat left ventricle: interactive effect of age and exercise training. J. Appl. Physiol. 2000, 89:1462-1468.
100. Chiao Y.A., Ramirez T.A., Zamilpa R., Okoronkwo S.M., Dai Q., Zhang J., et al. Matrix metalloproteinase-9 deletion attenuates myocardial fibrosis and diastolic dysfunction in aging mice. Cardiovasc. Res. 2012, 96:444-455.
101. Mays P.K., McAnulty R.J., Campa J.S., Lauquin G.J. Age-related changes in collagen synthesis and degradation in rat tissues: importance of degradation of newly synthesized collagen in regulating collagen production. Biochem. J. 1991, 276:307-313.
102. Besse S., Robert V., Assayag P., Delcayre C., Swynghedauw B. Nonsynchronous changes in myocardial collagen mRNA and protein during aging: effect of DOCA-salt hypertension. Am. J. Phys. 1994, 267. (H2237-H44).
103. Thomas D.P., McCormick R.J., Zimmerman S.D., Vadlamudi R.K., Gosselin L.E. Aging- and training-induced alterations in collagen characteristics of rat left ventricle and papillary muscle. Am. J. Physiol. Heart Circ. Physiol. 1992, 263. (H778-H83).
104. Campbell D.J., Somaratne J.B., Jenkins A.J., Prior D.L., Yii M., Kenny J.F., et al. Diastolic dysfunction of aging is independent of myocardial structure but associated with plasma advanced glycation end-product levels. PLoS One 2012, 7.
105. Asif M., Egan J., Vasan S., Jyothirmayi G.N., Masurekar M.R., Lopez S., et al. An advanced glycation endproduct cross-link breaker can reverse age-related increases in myocardial stiffness. Proc. Natl. Acad. Sci. U. S. A. 2000, 97:2809-2813.
106. Lenzen S. The mechanisms of alloxan- and streptozotocin-induced diabetes. Diabetologia 2008, 51:216-226.
107. Liu J., Masurekar M.R., Vatner D.E., Jyothirmayi G.N., Regan T.J., Vatner S.F., et al. Glycation end-product cross-link breaker reduces collagen and improves cardiac function in aging diabetic heart. Am. J. Physiol. Heart Circ. Physiol. 2003, 285:H2587-H2591.
108. McCurdy S., Baicu C.F., Heymans S., Bradshaw A.D. Cardiac extracellular matrix remodeling: fibrillar collagens and secreted protein acidic and rich in cysteine (SPARC). J. Mol. Cell. Cardiol. 2010, 48:544-549.
109. Bradshaw A.D., Baicu C.F., Rentz T.J., Van Laer A.O., Bonnema D.D., Zile M.R. Age-dependent alterations in fibrillar collagen content and myocardial diastolic function: role of SPARC in post-synthetic procollagen processing. Am. J. Physiol. Heart Circ. Physiol. 2010, 298. (H614-H22).
110. de Castro Bras L.E., Toba H., Baicu C.F., Zile M.R., Weintraub S.T., Lindsey M.L., et al. Age and SPARC change the extracellular matrix composition of the left ventricle. Biomed. Res. Int. 2014, 2014:810562.
111. Bradshaw A.D. The role of secreted protein acidic and rich in cysteine (SPARC) in cardiac repair and fibrosis: Does expression of SPARC by macrophages influence outcomes?. J. Mol. Cell. Cardiol. 2016, 93:156-161. (in this issue).
112. Burstein B., Nattel S. Atrial fibrosis: mechanisms and clinical relevance in atrial fibrillation. J. Am. Coll. Cardiol. 2008, 51:802-809.
113. Silver M.A., Pick R., Brilla C.G., Jalil J.E., Janicki J.S., Weber K.T. Reactive and reparative fibrillar collagen remodelling in the hypertrophied rat left ventricle: two experimental models of myocardial fibrosis. Cardiovasc. Res. 1990, 24:741-747.
114. Jellis C., Martin J., Narula J., Marwick T.H. Assessment of nonischemic myocardial fibrosis. J. Am. Coll. Cardiol. 2010, 56:89-97.
115. Schalla S., Bekkers S.C., Dennert R., van Suylen R.J., Waltenberger J., Leiner T., et al. Replacement and reactive myocardial fibrosis in idiopathic dilated cardiomyopathy: comparison of magnetic resonance imaging with right ventricular biopsy. Eur. J. Heart Fail. 2010, 12:227-231.
116. Creemers E.E., Pinto Y.M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc. Res. 2011, 89:265-272.
117. Comtois P., Nattel S. Interactions between cardiac fibrosis spatial pattern and ionic remodeling on electrical wave propagation. Conf. Proc. IEEE Eng. Med. Biol. Soc. 2011, 2011:4669-4672.
118. Kawara T., Derksen R., de Groot J.R., Coronel R., Tasseron S., Linnenbank A.C., et al. Activation delay after premature stimulation in chronically diseased human myocardium relates to the architecture of interstitial fibrosis. Circulation 2001, 104:3069-3075.
119. Nicoletti A., Michel J.B. Cardiac fibrosis and inflammation: interaction with hemodynamic and hormonal factors. Cardiovasc. Res. 1999, 41:532-543.
120. Macri S.C., Bailey C.C., de Oca N.M., Silva N.A., Rosene D.L., Mansfield K.G., et al. Immunophenotypic alterations in resident immune cells and myocardial fibrosis in the aging rhesus macaque (Macaca mulatta) heart. Toxicol. Pathol. 2012, 40:637-646.
121. Dai Z., Aoki T., Fukumoto Y., Shimokawa H. Coronary perivascular fibrosis is associated with impairment of coronary blood flow in patients with non-ischemic heart failure. J. Cardiol. 2012, 60:416-421.
122. van den Heuvel A.F., van Veldhuisen D.J., van der Wall E.E., Blanksma P.K., Siebelink H.M., Vaalburg W.M., et al. Regional myocardial blood flow reserve impairment and metabolic changes suggesting myocardial ischemia in patients with idiopathic dilated cardiomyopathy. J. Am. Coll. Cardiol. 2000, 35:19-28.
123. Yamamoto K., Masuyama T., Sakata Y., Nishikawa N., Mano T., Yoshida J., et al. Myocardial stiffness is determined by ventricular fibrosis, but not by compensatory or excessive hypertrophy in hypertensive heart. Cardiovasc. Res. 2002, 55:76-82.
124. Martos R., Baugh J., Ledwidge M., O'Loughlin C., Conlon C., Patle A., et al. Diastolic heart failure: evidence of increased myocardial collagen turnover linked to diastolic dysfunction. Circulation 2007, 115:888-895.
125. Lindsey M.L., Goshorn D.K., Squires C.E., Escobar G.P., Hendrick J.W., Mingoia J.T., et al. Age-dependent changes in myocardial matrix metalloproteinase/tissue inhibitor of metalloproteinase profiles and fibroblast function. Cardiovasc. Res. 2005, 66:410-419.
126. Robert V., Besse S., Sabri A., Silvestre J.S., Assayag P., Nguyen V.T., et al. Differential regulation of matrix metalloproteinases associated with aging and hypertension in the rat heart. Lab. Investig. 1997, 76:729-738.
127. Nagase H., Visse R., Murphy G. Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc. Res. 2006, 69:562-573.
128. Lindsey M.L., Iyer R.P., Jung M., DeLeon-Pennell K., Ma Y. Matrix metalloproteinases as input and output signals for post-myocardial infarction remodeling. J. Mol. Cell. Cardiol. 2016, 91:134-140. (in this issue).
129. Giannandrea M., Parks W.C. Diverse functions of matrix metalloproteinases during fibrosis. Dis. Model. Mech. 2014, 7:193-203.
130. Bonnema D.D., Webb C.S., Pennington W.R., Stroud R.E., Leonardi A.E., Clark L.L., et al. Effects of age on plasma matrix metalloproteinases (MMPs) and tissue inhibitor of metalloproteinases (TIMPs). J. Card. Fail. 2007, 13:530-540.
131. Yu Q., Stamenkovic I. Cell surface-localized matrix metalloproteinase-9 proteolytically activates TGF-beta and promotes tumor invasion and angiogenesis. Genes Dev. 2000, 14:163-176.
132. Chiao Y.A., Dai Q., Zhang J., Lin J., Lopez E.F., Ahuja S.S., et al. Multi-analyte profiling reveals matrix metalloproteinase-9 and monocyte chemotactic protein-1 as plasma biomarkers of cardiac aging. Circ. Cardiovasc. Genet. 2011, 4:455-462.
133. Spinale F.G., Escobar G.P., Mukherjee R., Zavadzkas J.A., Saunders S.M., Jeffords L.B., et al. Cardiac-restricted overexpression of membrane type-1 matrix metalloproteinase in mice: effects on myocardial remodeling with aging. Circ. Heart Fail. 2009, 2:351-360.
134. Bujak M., Kweon H.J., Chatila K., Li N., Taffet G., Frangogiannis N.G. Aging-related defects are associated with adverse cardiac remodeling in a mouse model of reperfused myocardial infarction. J. Am. Coll. Cardiol. 2008, 51:1384-1392.
135. Jugdutt B.I., Palaniyappan A., Uwiera R.R., Idikio H. Role of healing-specific-matricellular proteins and matrix metalloproteinases in age-related enhanced early remodeling after reperfused STEMI in dogs. Mol. Cell. Biochem. 2009, 322:25-36.
136. Yabluchanskiy A., Ma Y., DeLeon-Pennell K.Y., Altara R., Halade G.V., Voorhees A.P., et al. Myocardial infarction superimposed on aging: MMP-9 deletion promotes M2 macrophage polarization. J. Gerontol. A Biol. Sci. Med. Sci. 2015.
137. Raya T.E., Gaballa M., Anderson P., Goldman S. Left ventricular function and remodeling after myocardial infarction in aging rats. Am. J. Physiol. Heart Circ. Physiol. 1997, 273. (H2652-H8).
138. Edgley A.J., Krum H., Kelly D.J. Targeting fibrosis for the treatment of heart failure: a role for transforming growth factor-beta. Cardiovasc. Ther. 2012, 30:e30-e40.
139. Dobaczewski M., Chen W., Frangogiannis N.G. Transforming growth factor (TGF)-beta signaling in cardiac remodeling. J. Mol. Cell. Cardiol. 2011, 51:600-606.
140. Macdonald P.S. Combined angiotensin receptor/neprilysin inhibitors: a review of the new paradigm in the management of chronic heart failure. Clin. Ther. 2015.
141. von Lueder T.G., Sangaralingham S.J., Wang B.H., Kompa A.R., Atar D., Burnett J.C., et al. Renin-angiotensin blockade combined with natriuretic peptide system augmentation: novel therapeutic concepts to combat heart failure. Circ. Heart Fail. 2013, 6:594-605.
142. Lang C.C., Struthers A.D. Targeting the renin-angiotensin-aldosterone system in heart failure. Nat. Rev. Cardiol. 2013, 10:125-134.
143. Du X.J., Bathgate R.A., Samuel C.S., Dart A.M., Summers R.J. Cardiovascular effects of relaxin: from basic science to clinical therapy. Nat. Rev. Cardiol. 2010, 7:48-58.
144. Teerlink J.R., Cotter G., Davison B.A., Felker G.M., Filippatos G., Greenberg B.H., et al. Serelaxin, recombinant human relaxin-2, for treatment of acute heart failure (RELAX-AHF): a randomised, placebo-controlled trial. Lancet 2013, 381:29-39.
145. Filippatos G., Teerlink J.R., Farmakis D., Cotter G., Davison B.A., Felker G.M., et al. Serelaxin in acute heart failure patients with preserved left ventricular ejection fraction: results from the RELAX-AHF trial. Eur. Heart J. 2014, 35:1041-1050.
146. Unemori E.N., Pickford L.B., Salles A.L., Piercy C.E., Grove B.H., Erikson M.E., et al. Relaxin induces an extracellular matrix-degrading phenotype in human lung fibroblasts in vitro and inhibits lung fibrosis in a murine model in vivo. J. Clin. Invest. 1996, 98:2739-2745.
147. Williams E.J., Benyon R.C., Trim N., Hadwin R., Grove B.H., Arthur M.J., et al. Relaxin inhibits effective collagen deposition by cultured hepatic stellate cells and decreases rat liver fibrosis in vivo. Gut 2001, 49:577-583.
148. Samuel C.S., Cendrawan S., Gao X.M., Ming Z., Zhao C., Kiriazis H., et al. Relaxin remodels fibrotic healing following myocardial infarction. Lab. Investig. 2011, 91:675-690.
149. Samuel C.S., Bodaragama H., Chew J.Y., Widdop R.E., Royce S.G., Hewitson T.D. Serelaxin is a more efficacious antifibrotic than enalapril in an experimental model of heart disease. Hypertension 2014, 64:315-322.
150. Parikh A., Patel D.R., CF M.T., Xiang W., Haney J., Yang L., et al. Relaxin suppresses atrial fibrillation by reversing fibrosis and myocyte hypertrophy, and increasing conduction velocity and sodium current in spontaneously hypertensive rat hearts. Circ. Res. 2013.
151. Samuel C.S., Unemori E.N., Mookerjee I., Bathgate R.A., Layfield S.L., Mak J., et al. Relaxin modulates cardiac fibroblast proliferation, differentiation, and collagen production and reverses cardiac fibrosis in vivo. Endocrinology 2004, 145:4125-4133.
152. Samuel C.S., Zhao C., Bathgate R.A., Du X.J., Summers R.J., Amento E.P., et al. The relaxin gene-knockout mouse: a model of progressive fibrosis. Ann. N. Y. Acad. Sci. 2005, 1041:173-181.
153. Heymans S., Gonzalez A., Pizard A., Papageorgiou A.P., Lopez-Andres N., Jaisser F., et al. Searching for new mechanisms of myocardial fibrosis with diagnostic and/or therapeutic potential. Eur. J. Heart Fail. 2015, 17:764-771.
154. Ochieng J., Furtak V., Lukyanov P. Extracellular functions of galectin-3. Glycoconj. J. 2004, 19:527-535.
155. Puthenedam M., Wu F., Shetye A., Michaels A., Rhee K.J., Kwon J.H. Matrilysin-1 (MMP7) cleaves galectin-3 and inhibits wound healing in intestinal epithelial cells. Inflamm. Bowel Dis. 2011, 17:260-267.
156. Ochieng J., Fridman R., Nangia-Makker P., Kleiner D.E., Liotta L.A., Stetler-Stevenson W.G., et al. Galectin-3 is a novel substrate for human matrix metalloproteinases-2 and -9. Biochemistry 1994, 33:14109-14114.
157. Felker G.M., Fiuzat M., Shaw L.K., Clare R., Whellan D.J., Bettari L., et al. Galectin-3 in ambulatory patients with heart failure: results from the HF-ACTION study. Circ. Heart Fail. 2012, 5:72-78.
158. Edelmann F., Holzendorf V., Wachter R., Nolte K., Schmidt A.G., Kraigher-Krainer E., et al. Galectin-3 in patients with heart failure with preserved ejection fraction: results from the Aldo-DHF trial. Eur. J. Heart Fail. 2015, 17:214-223.
159. Meijers W.C., Januzzi J.L., de Filippi C., Adourian A.S., Shah S.J., van Veldhuisen D.J., et al. Elevated plasma galectin-3 is associated with near-term rehospitalization in heart failure: a pooled analysis of 3 clinical trials. Am. Heart J. 2014, 167:853-860. e4.
160. Moriguchi A., Brosnihan K.B., Kumagai H., Ganten D., Ferrario C.M. Mechanisms of hypertension in transgenic rats expressing the mouse Ren-2 gene. Am. J. Phys. 1994, 266:R1273-R1279.
161. Sharma U.C., Pokharel S., van Brakel T.J., van Berlo J.H., Cleutjens J.P.M., Schroen B., et al. Galectin-3 marks activated macrophages in failure-prone hypertrophied hearts and contributes to cardiac dysfunction. Circulation 2004, 110:3121-3128.
162. Calvier L., Martinez-Martinez E., Miana M., Cachofeiro V., Rousseau E., Sadaba J.R., et al. The impact of galectin-3 inhibition on aldosterone-induced cardiac and renal injuries. JACC Heart Fail. 2015, 3:59-67.
163. Martínez-Martínez E., Calvier L., Fernández-Celis A., Rousseau E., Jurado-López R., Rossoni L.V., et al. Galectin-3 blockade inhibits cardiac inflammation and fibrosis in experimental hyperaldosteronism and hypertension. Hypertension 2015.
164. Lepojarvi E.S., Piira O.P., Paakko E., Lammentausta E., Risteli J., Miettinen J.A., et al. Serum PINP, PIIINP, galectin-3, and ST2 as surrogates of myocardial fibrosis and echocardiographic left venticular diastolic filling properties. Front. Physiol. 2015, 6:200.
165. Ho J.E., Liu C., Lyass A., Courchesne P., Pencina M.J., Vasan R.S., et al. Galectin-3, a marker of cardiac fibrosis, predicts incident heart failure in the community. J. Am. Coll. Cardiol. 2012, 60:1249-1256.
166. de Boer R.A., van Veldhuisen D.J., Gansevoort R.T., Muller Kobold A.C., van Gilst W.H., Hillege H.L., et al. The fibrosis marker galectin-3 and outcome in the general population. J. Intern. Med. 2012, 272:55-64.
167. Lok D.J., Lok S.I., de la Porte PW B.-A., Badings E., Lipsic E., van Wijngaarden J., et al. Galectin-3 is an independent marker for ventricular remodeling and mortality in patients with chronic heart failure. Clin. Res. Cardiol. 2013, 102:103-110.
168. AbouEzzeddine O.F., Haines P., Stevens S., Nativi-Nicolau J., Felker G.M., Borlaug B.A., et al. Galectin-3 in heart failure with preserved ejection fraction. A RELAX trial substudy (phosphodiesterase-5 inhibition to improve clinical status and exercise capacity in diastolic heart failure). JACC Heart Fail. 2015, 3:245-252.
169. Pan J., Fukuda K., Saito M., Matsuzaki J., Kodama H., Sano M., et al. Mechanical stretch activates the JAK/STAT pathway in rat cardiomyocytes. Circ. Res. 1999, 84:1127-1136.
170. Celik A., Sahin S., Koc F., Karayakali M., Sahin M., Benli I., et al. Cardiotrophin-1 plasma levels are increased in patients with diastolic heart failure. Med. Sci. Monit. 2012, 18:CR25-CR31.
171. Song K., Wang S., Huang B., Luciano A., Srivastava R., Mani A. Plasma cardiotrophin-1 levels are associated with hypertensive heart disease: a meta-analysis. J. Clin. Hypertens. (Greenwich) 2014, 16:686-692.
172. Bristow M.R., Long C.S. Cardiotrophin-1 in heart failure. Circulation 2002, 106:1430-1432.
173. Sheng Z., Knowlton K., Chen J., Hoshijima M., Brown J.H., Chien K.R. Cardiotrophin 1 (CT-1) inhibition of cardiac myocyte apoptosis via a mitogen-activated protein kinase-dependent pathway. Divergence from downstream CT-1 signals for myocardial cell hypertrophy. J. Biol. Chem. 1997, 272:5783-5791.
174. López B., González A., Querejeta R., Larman M., Rábago G., Díez J. Association of cardiotrophin-1 with myocardial fibrosis in hypertensive patients with heart failure. Hypertension 2014, 63:483-489.
175. López-Andrés N., Calvier L., Labat C., Fay R., Díez J., Benetos A., et al. Absence of cardiotrophin 1 is associated with decreased age-dependent arterial stiffness and increased longevity in mice. Hypertension 2013, 61:120-129.
176. Thum T. Noncoding RNAs and myocardial fibrosis. Nat. Rev. Cardiol. 2014, 11:655-663.
177. Ambros V. The functions of animal microRNAs. Nature 2004, 431:350-355.
178. Boon R.A., Dimmeler S. MicroRNAs in myocardial infarction. Nat. Rev. Cardiol. 2015, 12:135-142.
179. Wijnen W.J., Pinto Y.M., Creemers E.E. The therapeutic potential of miRNAs in cardiac fibrosis: where do we stand?. J. Cardiovasc. Transl. Res. 2013, 6:899-908.
180. van Rooij E., Olson E.N. MicroRNA therapeutics for cardiovascular disease: opportunities and obstacles. Nat. Rev. Drug Discov. 2012, 11:860-872.
181. van Rooij E., Kauppinen S. Development of microRNA therapeutics is coming of age. EMBO Mol. Med. 2014, 6:851-864.
182. Thum T. MicroRNA therapeutics in cardiovascular medicine. EMBO Mol. Med. 2012, 4:3-14.
183. Jazbutyte V., Fiedler J., Kneitz S., Galuppo P., Just A., Holzmann A., et al. MicroRNA-22 increases senescence and activates cardiac fibroblasts in the aging heart. Age 2013, 35:747-762.
184. Boon R.A., Iekushi K., Lechner S., Seeger T., Fischer A., Heydt S., et al. MicroRNA-34a regulates cardiac aging and function. Nature 2013, 495:107-110.
185. Badi I., Burba I., Ruggeri C., Zeni F., Bertolotti M., Scopece A., et al. MicroRNA-34a induces vascular smooth muscle cells senescence by SIRT1 downregulation and promotes the expression of age-associated pro-inflammatory secretory factors. J. Gerontol. A Biol. Sci. Med. Sci. 2014.
186. van Almen G.C., Verhesen W., van Leeuwen R.E., van de Vrie M., Eurlings C., Schellings M.W., et al. MicroRNA-18 and microRNA-19 regulate CTGF and TSP-1 expression in age-related heart failure. Aging Cell 2011, 10:769-779.
187. Du W.W., Li X., Li T., Li H., Khorshidi A., Liu F., et al. The microRNA miR-17-3p inhibits mouse cardiac fibroblast senescence by targeting Par4. J. Cell Sci. 2015, 128:293-304.
188. Hackl M., Brunner S., Fortschegger K., Schreiner C., Micutkova L., Muck C., et al. miR-17, miR-19b, miR-20a, and miR-106a are down-regulated in human aging. Aging Cell 2010, 9:291-296.
189. Singh M., Foster C.R., Dalal S., Singh K. Role of osteopontin in heart failure associated with aging. Heart Fail. Rev. 2010, 15:487-494.
190. Frangogiannis N.G. Matricellular proteins in cardiac adaptation and disease. Physiol. Rev. 2012, 92:635-688.
191. Lenga Y., Koh A., Perera A.S., McCulloch C.A., Sodek J., Zohar R. Osteopontin expression is required for myofibroblast differentiation. Circ. Res. 2008, 102:319-327.
192. Trueblood N.A., Xie Z., Communal C., Sam F., Ngoy S., Liaw L., et al. Exaggerated left ventricular dilation and reduced collagen deposition after myocardial infarction in mice lacking osteopontin. Circ. Res. 2001, 88:1080-1087.
193. Behnes M., Brueckmann M., Lang S., Espeter F., Weiss C., Neumaier M., et al. Diagnostic and prognostic value of osteopontin in patients with acute congestive heart failure. Eur. J. Heart Fail. 2013, 15:1390-1400.
194. Rosenberg M., Zugck C., Nelles M., Juenger C., Frank D., Remppis A., et al. Osteopontin, a new prognostic biomarker in patients with chronic heart failure. Circ. Heart Fail. 2008, 1:43-49.
195. Miller S.J., Watson W.C., Kerr K.A., Labarrere C.A., Chen N.X., Deeg M.A., et al. Development of progressive aortic vasculopathy in a rat model of aging. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H2634-H2643.
196. Lorenzen J.M., Schauerte C., Hubner A., Kolling M., Martino F., Scherf K., et al. Osteopontin is indispensible for AP1-mediated angiotensin II-related miR-21 transcription during cardiac fibrosis. Eur. Heart J. 2015, 36:2184-2196.
197. Thum T., Gross C., Fiedler J., Fischer T., Kissler S., Bussen M., et al. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature 2008, 456:980-984.
198. Ardite E., Perdiguero E., Vidal B., Gutarra S., Serrano A.L., Munoz-Canoves P. PAI-1-regulated miR-21 defines a novel age-associated fibrogenic pathway in muscular dystrophy. J. Cell Biol. 2012, 196:163-175.
199. Unemori E.N., Amento E.P. Relaxin modulates synthesis and secretion of procollagenase and collagen by human dermal fibroblasts. J. Biol. Chem. 1990, 265:10681-10685.
200. Yu L., Ruifrok W.P.T., Meissner M., Bos E.M., van Goor H., Sanjabi B., et al. Genetic and pharmacological inhibition of galectin-3 prevents cardiac remodeling by interfering with myocardial fibrogenesis. Circ. Heart Fail. 2013, 6:107-117.
201. Lopez-Andres N., Rousseau A., Akhtar R., Calvier L., Inigo C., Labat C., et al. Cardiotrophin 1 is involved in cardiac, vascular, and renal fibrosis and dysfunction. Hypertension 2012, 60:563-573.
202. Drobic V., Cunnington R.H., Bedosky K.M., Raizman J.E., Elimban V.V., Rattan S.G., et al. Differential and combined effects of cardiotrophin-1 and TGF-beta1 on cardiac myofibroblast proliferation and contraction. Am. J. Physiol. Heart Circ. Physiol. 2007, 293:H1053-H1064.
203. Dobaczewski M., Bujak M., Zymek P., Ren G., Entman M.L., Frangogiannis N.G. Extracellular matrix remodeling in canine and mouse myocardial infarcts. Cell Tissue Res. 2006, 324:475-488.
204. Lindsey M.L., Zouein F.A., Tian Y., Padmanabhan Iyer R., de Castro Bras L.E. Osteopontin is proteolytically processed by matrix metalloproteinase 9. Can. J. Physiol. Pharmacol. 2015, 1-8.